Background
Pre-clinical research: inflammation in animal models of ASD and schizophrenia
Disease | Animal model | Trigger | Main features and outcomes | Inflammatory molecules, cells and processes | References |
---|---|---|---|---|---|
Genetic models | |||||
ASD | BTBR mice | Crossing of inbred strain at (non-agouti; black and tan) and wild-type T (brachyury) mutations, with mice carrying tufted (Itpr3tf) allele | Avoid social interaction; increased repetitive behaviors; altered functional connectivity; loss of corpus callosum; formation of the cortical area and interhemispheric connectivity altered in an age- and region-specific manner; altered oxidative stress mechanisms | Higher brain-reactive IgG levels; increased microglia activation; increased pro-inflammatory cytokines (IL-1b, IL-18 and IL-33, IL-6, IL-12); decreased B cells; increased numbers of CD4 T cells; enhanced M1 macrophage polarization | Careaga et al. 2015; Fenlon et al. 2015; Heo et al. 2011; Hwang et al. 2015; Kim et al. 2016; Meyza et al. 2013; Onore et al. 2013; Sforazzini et al. 2014; Shpyleva, Ivanovsky, 2014 |
ASD/Rett syndrome | Mecp2 mutant mice and non-human primates | Mecp2 gene mutation or duplication | Model of Rett syndrome. Repetitive locomotion, increased anxiety, reduced social interaction, and relatively weak cognitive phenotypes | Activation, followed by loss of microglia and some monocytes and macrophage populations (e.g., meningeal) | Cronk et al. 2015; Liu et al. 2016 |
Schizophrenia | DISC1 mutant mice | DISC1 gene mutation | Alteration in brain connectivity and function during development; behavioral and cognitive impairments; anatomical, cell biological, and circuitry deficits | Impaired GSK-3b signaling; higher IL-1b and IL-5 in fetal brain | Flores, Morales-Medina, 2016; Tomoda et al. 2016; Abazyan et al. 2010 |
Neurodevelopmental models | |||||
ASD | Pre-natal stress/exposure models | e.g., administration of VPA during pregnancy | Decreased social interaction in adult males; reduced cognitive function | Increased basal glial activation; altered systemic inflammation; changes in immunity-related gene expression; increased intestinal inflammation | Lucchina and Depino, 2014; Huang et al. 2016; de Theije et al. 2014; Hill, 2015 |
ASD and schizophrenia | Maternal immune activation (MIA) in mice or primates | Maternal infection or immune stimulation (LPS, PolyI:C,) | Reduced PPI and ultrasonic vocalizations; decreased sociability and increased repetitive or stereotyped behavior; involvement of parvalbumin expressing interneurons in medial pre-frontal cortex; neurochemical and brain morphological abnormalities (enlarged ventricles; spatially localized deficit in Purkinje cells); decreased neurogenesis; impaired synaptic development | Maternal cytokine upregulation (IL-1β, IL-6, TNF-α IL-17, IL-10); fetal and neonatal increased cytokine levels in areas of the brain (frontal and cingulated cortex, and hippocampus) and in serum; increased cytokine and chemokine expression in the fetal brain; controversy on increased levels of microglial activation | Choi et al., 2016; Canetta et al. 2016; Garay, Hsiao, 2013; Smith et al. 2007; Juckel et al. 2011, Mattei et al. 2014, Van den Eynde et al. 2014; Pratt, Ni, 2013; (Giovanoli et al. 2015, Missault, Van den Eynde, 2014, Smolders et al. 2015; Coiro et al. 2015; Machado et al. 2015) |
Schizophrenia | Neonatal ventral hippocampal lesion | Microinjection of Ibotenic acid in the ventral hippocampus at postnatal day 7 | Abnormal behavioral phenotypes after puberty; Persistent astrogliosis and microglial activation; increase in metabotropic glutamate receptor type 5 (mGluR5); hippocampal neuronal loss | Persistent astrogliosis and microglial activation; Increased production of inflammatory mediators; Increased mGluR5 expression in astrocytes and microglia | Drouin-Ouellet et al. 2011; Hill, 2015 |
Combination models | |||||
Schizophrenia | Combination of genetic and environmental factors (G × E) | MIA in the DISC1 mutant models | Developmental stage-specific deficits in social behavior, spatial working memory, and PPI; decreased volume of amygdala, hypothalamus, and periaqueductal gray matter; decreased 5-HT metabolism | Higher IL-6 in response to polyI:C in fetal brain in DiSC1 mutant mice; high IL-1β, reduced GSK-3β signaling and IL-5 in response to PolyI:C | Abazyan et al. 2010, Meyer, 2014; O’Leary, Desbonnet, 2014; Lipina et al. 2013 |
ASD and schizophrenia | Combination of 2 environmental factors (E × E) | MIA model combined with other post-natal stressors, like being reared by stressed mother, or pubertal stress exposure | Impaired working and spatial memory from pre-natal, but not postnatal maternal influence; combination of MIA with peri-pubertal stress led to neuropathological effects in the hippocampus GABAergic cell population | Transient neuroinflammation | Giovanoli, Weber, 2014; Richetto, Calabrese, 2013; Meyer, 2014 |
Modeling the genetic contribution to ASD and schizophrenia
Neurodevelopmental models of ASD and schizophrenia
Combining different models to better mimic ASD and schizophrenia
Microglia: a key player in human neuroinflammation
Feature | ASD | Schizophrenia | Proposed implication |
---|---|---|---|
General effects | |||
Overall deregulation of the immune system with increased production of pro-inflammatory cytokines, possible as a result of the activation of microglia | (Patterson, 2009; Rodriguez and Kern, 2011; Takano, 2015) | (Patterson, 2009; Takahashi et al. 2016) | Upregulation of iNOS, glutaminase, and inducible cyclooxygenase (COX-2) leading to an increase of nitric oxide (NO), glutamate and prostaglandins, respectively. These substances have a toxic effect in neurons(Fernandes et al. 2014) |
Specific effects—data from analysis of biological materials | |||
Decrease in NK cell function, possibly as a result of increased production of NO by microglia | Enstrom et al., 2009)(Warren et al. 1987) | (Karpinski et al. 2016) | NK cells play important functions in innate immunity, sppecially against intracellular infections. Disfunction of NK cells may predispose to adverse neuroimmune interactions, namely, during development. |
Glutathione (GSH) depletion, possibly caused by i-NOS increase | (Rodriguez and Kern, 2011) | (Ivanova et al. 2015; Zhang et al. 2016) | GSH (an antioxidant) has a protective effect on neurons. Its decrease may lead to easier neuron damage. |
Increase in anti-phospholipid antibodies (APLAs) | Careaga et al., 2013) | NF | Increased risk of blood clotting and pregnancy losses |
Denser distribution of microglia | In fronto-insular and visual cortex (Tetreault et al. 2012) | In pre-frontal white matter (Hercher et al. 2014). In frontal and temporal cortex(Garey, 2010) | Reduced number of neurons and/or disrupted neural connectivity |
Increased levels of glial fibrillary acidic protein (GFAP) in the brain | Cerebrospinal fluid (Ahlsen et al. 1993). Cerebelum(Bailey et al. 1998). Anterior cingulate cortex white matter(Crawford et al. 2015) | Frontal cortex (Rao et al. 2013) | GFAP is an important protein in the central nervous system, in particular in repair after CNS injury. An increase in GFAP is a hallmark of reactive gliosis (Kamphuis et al., 2015), which follows trauma or injury. |
Increases expression of NF-kB in activated microglia | (Young et al. 2011) | (Rao et al. 2013) | NF-kB plays a key role in inflammation, through its ability to induce transcription of pro-inflammatory genes. |
Presence of HLA-DR positive cells | In serum(Lee et al. 2006; Mead and Ashwood, 2015) | Brain, post-mortem (Bayer et al. 1999; Garey, 2010; Radewicz et al. 2000; Rao et al. 2013) | HLA-DR is an immunohistochemical marker that is expressed in antigen presenting cells (B lymphocytes, dendritic cells, macrophages). It reacts with activated microglia cells. |
Increase in calprotectin | Increased levels in feces(de Magistris et al. 2010) | Localization in microglia(Foster et al. 2006) | Calprotectin is a pro-inflammatory marker. Increased fecal levels are due to increased intestinal permeability. |
In vivo data | |||
Activation of microglia found by PET | (Suzuki et al. 2013) | (Bloomfield et al. 2016) | Confirms the importance of neuroinflammation in ASD and schizophrenia revealed by studies based on the analysis of tissues |
Activation of microglia in ASD and schizophrenia
Microglia in post-mortem studies of ASD and schizophrenia
Microglia in ASD and schizophrenia; in vivo studies
Clinical research: inflammatory cells and biomarkers in ASD and schizophrenia
Biomarkers and clinical features in ASD and schizophrenia
Biomarkers related to immune function and oxidative stress
Biomarker | Associated clinical features | References | |
---|---|---|---|
ASD | Schizophrenia | ||
Immune function | |||
IL-6 | ↑ in patients compared to controls; predominantly in children with regressive autism, associated with more impaired communication and aberrant behaviors; positive correlation with severity of autism and CARS scores | Ashwood et al. 2011; Yang et al. 2015 Chang-JiangYang et al. 2015 | |
↑ in patients compared to controls; correlated to negative symptoms and duration of illness | Kim et al. 2000 | ||
State marker | Miller et al. 2013 | ||
TNF-α | ↑ in patients compared to controls; positive correlation with the severity of autism; positively correlated to CARS scores | Yang et al. 2015 Chang-JiangYang et al. 2015 | |
↓ in patients compared to controls; negative correlation to PANSS total score, general psychopathology, positive and cognitive subscales | Lv, Tan, 2015; Noto, Maes, 2015a | ||
Trait marker | Miller et al. 2011 | ||
TNF-R1 and TNF-R2 | NF | TNF-R1 significantly correlated with positive symptoms (PANSS) | Hope et al. 2013 |
↑soluble forms, and associated with treatment resistance | Noto, Maes, 2015a | ||
IL-1β | ↑ in patients compared to controls; predominantly in children with regressive autism, associated with more impaired communication and aberrant behaviors | Ashwood et al. 2011 | |
State marker | Miller et al. 2011 | ||
IL-1RA | NF | Significantly correlated with negative symptoms (PANSS) | Hope et al. 2013 |
IL-12 | ↑ in patients compared to controls; predominantly in children with regressive autism, associated with more impaired communication and aberrant behaviors | Ashwood et al. 2011 | |
Trait marker | Miller et al. 2011 | ||
IFN-ϒ | NF | Trait marker | Miller et al. 2011 |
TGF-β | ↓TGF-β1 in autistic children compared to controls or children with other DD; significant correlation with reduced adaptive behaviors and worse behavioral symptoms | Ashwood et al. 2008 | |
State marker | Miller et al. 2013 | ||
Chemokines | ↑ osteopontin in autistic children compared to controls; positive correlation with CARS scores and disease severity | Al-Ayadhi and Mostafa, 2011 | |
↑ IL-8 in patients compared to controls; predominantly in children with regressive autism, associated with more impaired communication and aberrant behaviors | Ashwood et al. 2011 | ||
↑ CCL11 and MIP-1α; CCL11 positively associated with negative symptoms ↑ MCP-1 associated with treatment resistance ↓ IP-10 | Noto, Maes, 2015a | ||
IL-2 | NF | ↓ in patients than controls; Inversely associated with negative symptoms; in patients negative correlation between IL-2 and total score in negative subscale of PANSS | Noto, Maes, 2015a; Azevedo et al. 2014 |
↑ in patients compared to controls; significant inverse relationship with positive subscale of PANSS | Zhang et al. 2002 | ||
IL-2R | NF | Trait marker; ↑ in patients compared to controls; associated with Positive and Negative Syndrome Scale total scores, negative symptom and general psychopathology subscale scores | Miller et al. 2013; Bresee and Rapaport, 2009 |
Lymphocyte populations | ↑ total lymphocytes, ↑T lymphocytes CD3+; ↑T helper CD4+; ↑CD4/CD8; ↓proportion T lymphocytes CD3+ in drug naïve FEP | Miller et al. 2013 | |
NF | ↑ proportion of CD4+ and CD56+ in acutely relapsed patients; CD4/CD8 ratio in a state marker; CD56 is a trait marker | Miller et al. 2013 | |
Immunoglobulins and antibodies | ↓ plasma IgG and IgM in autistic children compared to other DD and healthy controls; correlated with behavioral severity in autistic children | NF | Heuer et al. 2008 |
↑ anti-ganglioside M1 in autistic children compared to healthy controls; correlated with disease severity and CARS scores | Mostafa and Al-Ayadhi, 2011 | ||
↑ anti-neuronal antibodies in autistic children compared to healthy controls; correlated with disease severity | Mostafa and Al-Ayadhi, 2012 | ||
Oxidative stress | |||
↓ pyridoxal | NF | Acute stage schizophrenia The greater the decrease in pyridoxal levels (admission to discharge) the less improvement in symptoms | Katsuta et al. 2014 |
↑ pentosodine ↓ pyridoxal | NF | Clinical features of treatment resistant schizophrenia; possible biomarkers | A rai et al. 2010; Miyashita et al. 2014 |
MicroRNAs: novel and promising biomarkers in schizophrenia and ASD
Disease | Samples | microRNAs | Reference | ||
---|---|---|---|---|---|
Type | Number | Downregulated | Upregulated | ||
Autism | Serum | 55 patients; 55 controls | miR-151a-3p, miR-181b-5p, miR-320a, miR-328, miR-433, miR-489, miR-572, miR-663a | miR-101–3p, miR-106b-5p, miR-130a-3p, miR-195-5p, miR-19b-3p | Mundalil Vasu et al. 2014 |
Peripheral blood | 20 patients; 20 controls | let-7a, let-7d, miR-103a, miR-1228 | miR-34b | Huang et al. 2015 | |
Schizophrenia | Plasma | 564 patients; 400 controls | NF | miR-130b, miR-193a-3p | Wei et al. 2015 |
PBMC | 90 patients; 60 controls | miR-432 | miR-34a, miR-449a, miR-564, miR-548d, miR-572, miR-652 | Lai et al. 2011 | |
Plasma | 50 patients; 50 controls | NF | miR-7 | Zhang et al. 2015 | |
Plasma and PBMC | 25 patients; 13 controls | NF | miR-132, miR-195, miR-30e, miR-7 in plasma; miR-212, miR-34a, miR-30e in PBMC | Sun, Lu et al. 2015a | |
Plasma | 61 patients; 62 controls | NF | miR-181b, miR-30e, miR-346, miR-34a, miR-7 | Sun, Zhang et al. 2015b | |
Serum | 145 patients; 40 controls | miR-195, miR-17 | miR-181b, miR-219-2-3p, miR-1308, let-7g, miR-346, miR-92a | Shi et al., 2012 | |
Plasma | 20 patients; 20 controls | NF | miRNA-181b, miRNA-30e, miRNA-34a, miRNA-7 | Song et al. 2014a |
Biomarkers and anti-psychotic treatment in ASD and schizophrenia
Effects of anti-psychotics on biomarkers of immune function and oxidative stress
Biomarker | Associated clinical features | References | |
---|---|---|---|
ASD | Schizophrenia | ||
Immune function | |||
IL-6 | NF | ↑ in drug-naïve FEP patients compared to healthy controls; ↓ after 10-week treatment with risperidone; ↓ in patients with depressive symptoms (but not in those without); clozapine treatment appears to ↑IL-6; treatment with typical anti-psychotics ↓ IL-6 and sIL-6R; ↓after anti-psychotic treatment in relapsed patients ↑IL-6R in patients compared to controls | Noto et al. 2015; Song et al. 2014b; Tourjman et al. 2013;Maes et al., 1995; Maes et al. 1997; Borovcanin et al. 2013; Drzyzga et al. 2006 |
TNF-α | NF | ↑ in drug-naïve FEP patients compared to healthy controls; ↓ after 10-week treatment with risperidone; ↓ in patients with depressive symptoms (but not in those without) | Noto et al. 2015 |
Anti-psychotic treatment reported to have no effect or ↓ levels of TNF-α; clozapine reported to ↑ TNF-α | Tourjman et al. 2013; Meyer et al. 2011; Drzyzga et al. 2006 | ||
sTNF-R | NF | Clozapine treatment appears to increase sTNF-R | Tourjman et al. 2013 |
IL-1β | NF | ↑ in drug-naïve FEP patients compared to healthy controls; after risperidone treatment levels returned to baseline at 6 months; ↓levels after anti-psychotic treatment | Song et al. 2014b; Tourjman et al. 2013; Meyer et al. 2011 |
IL-1RA | Levels did not change after 8-week treatment with risperidone despite clinical improvement | ↑ drug-naïve FEP patients; ↓ after 6-week treatment with risperidone or olanzapine anti-psychotic treatment reported to have no effect on IL-1RA; clozapine treatment↑ IL-1RA; ↑ sIL-1RA with anti-psychotic treatment | De Witte et al. 2014; Tourjman et al. 2013; Maes et al. 1997; Meyer et al. 2011; Tobiasova et al. 2011 |
IL-12 | NF | Possibly ↑ with anti-psychotic treatment | Tourjman et al. 2013 |
IFN-ϒ | Levels did not change after 8-week treatment with risperidone despite clinical improvement | ↓ after anti-psychotic treatment | Tourjman et al. 2013; Tobiasova et al. 2011 |
TGF-β | NF | ↑ in un-medicated FEP and schizophrenia relapse patients; further increased after treatment with anti-psychotics in FEP; unaffected by anti-psychotic treatment | Borovcanin et al. 2013; Tourjman et al. 2013 |
Chemokines | ↓ Eotaxin and MCP-1 after 8-week treatment with risperidone; MCP-1 levels did not change after 8-week treatment with risperidone despite clinical improvement in another study | Choi et al. 2013; Tobiasova et al. 2011 | |
↑EGF in children with ASD; levels did not change after 8-week treatment with risperidone despite clinical improvement | Tobiasova et al. 2011 | ||
↓CC16 in patients compared to controls; increase after treatment with clozapine | Maes et al. 1997 | ||
↑S100B in drug-naïve and medicated patients compared to controls and also in drug-naïve compared to medicated patients; ↓S100B with haloperidol and clozapine | Zhang, Xiu, 2010a; Zhang et al. 2010a (VER) | ||
IL-2 | NF | Unaffected by anti-psychotic treatment; ↓ by first and second generation anti-psychotics | Tourjman et al. 2013; Drzyzga et al. 2006 |
IL-2R | NF | Increased in younger patients; treatment with clozapine increases sIL-2R levels | Maes et al. 1994 |
IL-10 | ↑ drug-naïve FEP patients; ↓after treatment with risperidone or olanzapine; changes in IL-10 correlated with improvements in negative, general and total symptom scores; another study reported no effect of anti-psychotics on IL-10 | De Witte et al. 2014; Noto et al. 2015; Tourjman et al. 2013 | |
IL-4 | ↓ after 10-week treatment with risperidone; another study reported no effect with anti-psychotics; ↓ after anti-psychotic treatment in FEP and relapse patents | Noto et al. 2015; Tourjman et al. 2013; Borovcanin et al. 2013 | |
IL-15 | ↑ drug-naïve in FEP | De Witte et al. 2014 | |
IL-13, IL-17, IL-1 | ↓ IL-13 in children with ASD compared to controls; levels of IL-13, IL-17, and IL-1 did not change after 8-week treatment with risperidone despite clinical improvement | IL-13 possibly ↓ by anti-psychotic treatment | Tobiasova et al. 2011; Tourjman et al. 2013 |
IL-27 | ↓ after anti-psychotic treatment in FEP | Borovcanin et al. 2013 | |
Oxidative stress | |||
SOD and NO levels | NF | ↑in patients with schizophrenia compared to controls Risperidone and haloperidol ↓ superoxide dismutase levels (but not nitric oxide levels) ↓ SOD levels at baseline predicted greater symptom improvement during treatment and greater change in SOD was correlated with greater symptom improvement | Zhang et al. 2012b |
PON1 activity, TRAP, and LOOH levels | NF | ↓PON1 activity and ↑TRAP in FEP ↑PON1 activity and↓ LOOH levels after 11 weeks of risperidone treatment | Noto et al. 2015b |
Predictors of response to anti-psychotics
Biomarker | Response to antipsychotic | ASD | Schizophrenia |
---|---|---|---|
Genes | |||
HTR2A c.-1438G>A, DRD3 Ser9Gly, HTR2C c.-995G>A and ABCB1 c.1236C>T polymorphisms | Polymorphisms that predicted clinical improvement with risperidone in children with ASD | Correia et al., 2010 | NF |
GBP6, RABL5, RNF213, NFKBID, and RNF40 | Correlated with response to risperidone | Lit et al., 2012 | NF |
Multiple genes associated with neuronal cell growth | Associated with a positive response to risperidone | Bent & Hendren, 2010 | NF |
A-2518G polymorphism of the MCP-1 | Treatment resistance associated with the G-allele | NF | Mundo et al., 2005 |
SNAP-25 (Mnll polymorphism) | Associated with changes in PANSS after 14 weeks of antipsychotics | NF | Muller et al., 2005 |
5HTT gene | Association between the 5-HTT-LPR variants and early negative symptom response to treatment in FEP | NF | Vazquez-Bourgon et al., 2010 |
Minerals | |||
↓ body zinc status (while taking risperidone) | Associated with greater improvement in irritability | Arnold et al., 2010 | NF |
Hormones | |||
↓insulin levels at T0 | Predictors of symptom improvement after antipsychotic treatment | NF | Schwarz, Guest, 2012 |
leptin, proinsulin, TGF-α | Associated with differences between the short- and long-term relapse | ||
↑leptin, insulin, C-peptide | In patients who relapsed later but no change in those relapsing earlier | ||
Blunted CAR Diurnal cortisol levels CAR | FEP compared to controls negatively correlated with the number of recent stressful events positively correlated with a history of sexual childhood abuse | NF | Mondelli et al., 2010 |
Persistent ↓CAR, ↑IL-6 and IFN-ϒ | In non-responders (12 week treatment with antipsychotics) in FEP | NF | Mondelli et al., 2015 |
More blunted CAR | Associated with worse cognitive function | NF | Aas et al., 2011 |
Baseline postdexamethasone cortisol levels Persistent non-suppression of cortisol levels following the dexamethasone test after 4 weeks of antipsychotics | Unrelated to outcome at 4 weeks or 1 year Associated with poor clinical outcome | NF | Tandon et al., 1991 |
Neurotransmitters and metabolites | |||
↓pMHPG (plasma 3-methoxy-4-hydroxyphenylglycol) | FEP patients who responded to treatment (8 weeks of antipsychotics) | NF | Nagaoka et al., 1997 |
↑baseline pHVA and week-1 pHVA (plasma homovanillic acid) levels | In responders compared to non-responders of FEP following 6 weeks of antipsychotic treatment | NF | Koreen et al., 1994 |
Relatively normal striatal dopamine synthesis and elevated anterior cingulate cortex glutamate levels | Treatment resistance in schizophrenia | NF | Demjaha et al., 2014 |
↑pretreatment prolactin response to D-fenfluramine test | ↓ response to haloperidol in FEP | NF | Mohr et al., 1998 |
3-OHKY (3-hydroxykynurenine) quinolinic acid at baseline | Predicted improvement following 4 week treatment with antipsychotics in FEP (lowest concentrations associated with the greatest improvement) | NF | Condray et al., 2011 |